With global healthcare budgets under intense pressure, early choices on indication, evidence and positioning determine whether a therapy will command payer willingness to pay later on.
Identifying Opportunities and Defining Early Value
At Valid Insight, we combine payer-first thinking, data-driven analytics from the Bioscript Data Insights (BDI) team, and multi-therapy expertise across the Bioscript Group to help clients set a product on the right market access trajectory from day one.
Typical engagements at this stage include:
- Strategic identification of appropriate INN, ATC and DDD codes
- Landscape assessments
- Disease area and indications sequencing strategy
- Phase III evidence requirements
- Evidence reviews and gap analysis
- Early value assessment and scientific advice
- Payer-relevant TPP development and testing
At Valid Insight, we combine payer-first thinking, data-driven analytics from the Bioscript Data Insights (BDI) team, and multi-therapy expertise across the Bioscript Group to help clients set a product on the right market access trajectory from day one.
Typical engagements at this stage include:
- Strategic identification of appropriate INN, ATC and DDD codes
- Landscape assessments
- Disease area and indications sequencing strategy
- Phase III evidence requirements
- Evidence reviews and gap analysis
- Early value assessment and scientific advice
- Payer-relevant TPP development and testing
